Skip to content
10-Q

Quarterly Report

ANAPTYSBIO, INC ANAB

0001193125-26-219515

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 29.1M sh
Shares Diluted Q1 2026 · Mar 31, 2026 28.69M sh
Shares Diluted Q1 2026 · Mar 31, 2025 30.64M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $0
Stock Repurchased Q1 2026 · Mar 31, 2025 $4.42M
Capex Q1 2026 · Mar 31, 2026 $17K
Capex Q1 2026 · Mar 31, 2025 $35K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$25.92M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$10.7M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $248.47M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $238.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $12.75M
Stockholders Equity Q1 2026 · Dec 31, 2025 $37.21M
Stockholders Equity Q1 2026 · Mar 31, 2025 $34.02M
Stockholders Equity Q1 2026 · Dec 31, 2024 $70.87M
Current Liabilities Q1 2026 · Mar 31, 2026 $41.7M
Current Liabilities Q1 2026 · Dec 31, 2025 $38.63M
Current Assets Q1 2026 · Mar 31, 2026 $316.11M
Current Assets Q1 2026 · Dec 31, 2025 $350.25M
Total Assets Q1 2026 · Mar 31, 2026 $329.68M
Total Assets Q1 2026 · Dec 31, 2025 $364.4M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.84
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.28
Eps Basic Q1 2026 · Mar 31, 2026 −$1.84
Eps Basic Q1 2026 · Mar 31, 2025 −$1.28
Sga Expense Q1 2026 · Mar 31, 2026 $26.2M
Sga Expense Q1 2026 · Mar 31, 2025 $14.13M
Net Income Q1 2026 · Mar 31, 2026 −$52.88M
Net Income Q1 2026 · Mar 31, 2025 −$39.33M
Operating Income Q1 2026 · Mar 31, 2026 −$34.64M
Operating Income Q1 2026 · Mar 31, 2025 −$27.54M
Revenue Q1 2026 · Mar 31, 2026 $25.56M
Revenue Q1 2026 · Mar 31, 2025 $27.77M